奥希替尼治疗非小细胞肺癌患者的耐药机制研究进展

Abstract
Figure/Table
References (30)
Related Citation (15)

Download: PDF (696 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Osimertinib is a third-generation epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs). It is currently approved for first-line treatment of patients with advanced non-small cell lung cancer (NSCLC) with EGFR mutation and second-line treatment with T790M mutant NSCLC after the first-generation EGFR-TKIs treatment progresses. Clinical studies have shown that Osimertinib can significantly improve the progression-free survival (PFS) of NSCLC patients, but it also brings serious drug resistance problems. In recent years, studies have found that the first-line application of Osimertinib resistance mechanism mainly depends on the activation of EGFR pathway and bypass signaling pathway; the drug resistance mechanism produced by the second-line and second-line application of Osimertinib depends on the activation of the EGFR pathway, the bypass signaling pathway, and the transformation of the cell phenotype. Osimertinib has different drug resistance mechanisms at different times. In order to provide a theoretical basis for the prevention and treatment of Osimertinib resistance, this article will review the different drug resistance mechanisms and treatment strategies of Osimertinib from the perspective of clinical drug use time.

Key words： Non-small-cell-lung cancer Osimertinib Resistance

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	WANG Huiyi KANG Xiaohong

Cite this article:

WANG Huiyi KANG Xiaohong. Research progress on the drug resistance mechanism of Osimertinib in patients with non-small cell lung cancer[J]. 中国医药导报, 2020, 17(28): 32-35.

URL:

http://www.yiyaodaobao.com.cn/EN/ OR http://www.yiyaodaobao.com.cn/EN/Y2020/V17/I28/32

[1] Akamatsu H，Katakami N，Okamoto I，et al. Osimertinib in Japanese patients with EGFR T790M mutation-positive advanced non-small-cell lung cancer：AURA3 trial [J]. Cancer Sci，2018，109（6）：1930-1938.
[2] Cho BC，Chewaskulyong B，Lee KH，et al. Osimertinib versus Standard of Care EGFR TKI as First-Line Treatment in Patients with EGFRm Advanced NSCLC：FLAURA Asian Subset [J]. J Thorac Oncol，2019，14（1）：99-106.
[3] Jean BA，Maurice P，David P，et al. Real-life efficacy of Osimertinib in pretreated patients with advanced non-small cell lung cancer harboring EGFR T790M mutation [J]. Lung Can，2019，127：96-102.
[4] Cho BC，Cheng Y，Zhou C，et al. Mechanisms of acquired resistance to first-line Osimertinib：preliminary data from the phase Ⅲ FLAURA study [J]. Ann Oncol，2018，29（suppl 8）：viii740.
[5] Uchibori K，Inase N，Nishio M，et al. Identification of Mutation Accumulation as Resistance Mechanism Emerging in First-Line Osimertinib Treatment [J]. J Thorac Oncol，2018，13（7）：915-925.
[6] Niederst MJ，Hu H，Mulvey HE，et al. The allelic context of the C797S mutation acquired upon treatment with third generation EGFR inhibitors impacts sensitivity to subsequent treatment strategies [J]. Clin Cancer Res，2015，21：3924-3933.
[7] Minari R，Bordi P，La Monica S，et al. Concurrent Acquired BRAF V600E Mutation and MET Amplification as Resistance Mechanism of First-Line Osimertinib Treatment in a Patient with EGFR-Mutated NSCLC [J]. J Thorac Oncol，2018，13：e89-e91.
[8] Oxnard GR，Hu Y，Mileham KF，et al. Assessment of Resistance Mechanisms and Clinical Implications in Patients with EGFR T790M-Positive Lung Cancer and Acquired Resistance to Osimertinib [J]. JAMA Oncol，2018，4（11）：1527-1534.
[9] Thress KS，Paweletz CP，Felip E，et al. Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M [J]. Nat Med，2015，21（6）：560-562.
[10] Piotrowska Z，Nagy R，Fairclough S，et al. OA 09.01 Characterizing the Genomic Landscape of EGFR C797S in Lung Cancer Using ctDNA Next-Generation Sequencing [J]. J Thorac Oncol，2017，12（11）：S1767.
[11] Arulananda S，Do H，Musafer A，et al. Combination Osimertinib and Gefitinib in C797S and T790M EGFR-Mutated Non-Small Cell Lung Cancer [J]. J Thorac Oncol，2017，12（11）：1728-1732.
[12] Wang Z，Yang JJ，Huang J，et al. Brief Report：Lung adenocarcinoma harboring，EGFR，T790M and， in trans，C797S responds to combination therapy of first and third generation EGFR-TKIs and shifts allelic configuration at resistance [J]. J Thorac Oncol，2017，12：1723-1727.
[13] Chia PL，Do H，Morey A，et al. Temporal changes of EGFR mutations and T790M levels in tumor and plasma DNA following AZD9291 treatment [J]. Lung Can，2016，98：29-32.
[14] Lin CC，Shih JY，Yu CJ，et al. Outcomes in patients with non-small-cell lung cancer and acquired Thr790Met mutation treated with Osimertinib：a genomic study [J]. Lancet Respir Med，2018，6（2）：107-116.
[15] Planchard D，Loriot Y，André F，et al. EGFR independent mechanisms of acquired resistance to AZD9291 in EGFR T790M-positive NSCLC patients [J]. Ann Oncol，2015，26（10）：2073-2078.
[16] Ou SI，Agarwal N，Ali SM. High MET amplification level as a resistance mechanism to Osimertinib （AZD9291） in a patient that symptomatically responded to crizotinib treatment post-Osimertinib progression [J]. Lung Can，2016，98：59-61.
[17] La Monica S，Cretella D，Bonelli M，et al. Trastuzumab emtansine delays and overcomes resistance to the third-generation EGFR-TKI Osimertinib in NSCLC EGFR mutated cell lines [J]. J Exp Clin Cancer Res，2017，36（1）：174.
[18] Ortiz-Cuaran S，Scheffler M，Plenker D，et al. Heterogeneous mechanisms of primary and acquired resistance to third-generation EGFR inhibitors [J]. Clin Cancer Res，2016，22（19）：4837-4847.
[19] Ramalingam SS，Yang CH，Lee CK，et al. Osimertinib As First-Line Treatment of EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer [J]. J Clin Oncol，2018，36（9）：841-849.
[20] Oxnard GR，Thress K，Paweletz C，et al. Mechanisms of Acquired Resistance to AZD9291 in EGFR T790M Positive Lung Cancer [J]. J Thorac Oncol，2015，10（9）：S207.
[21] Chabon JJ，Simmons AD，Lovejoy AF，et al. Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients [J]. Nat Commun，2016，7：11815.
[22] Dong C，Yang R，LI H，et al. Econazole nitrate inhibits PI3K activity and promotes apoptosis in lung cancer cells [J]. Sci Rep，2017，7（1）：17987.
[23] Eberlein CA，Stetson D，Markovets AA，et al. Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models [J]. Cancer Res，2015，75（12）：2489-2500.
[24] Ho CC，Liao WY，Lin CA，et al. Acquired BRAF V600E Mutation as Resistant Mechanism after Treatment with Osimertinib [J]. J Thorac Oncol，2017，12（3）：567-572.
[25] Ohashi K，Sequist LV，Arcila ME，et al. Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS，NRAS，or MEK1 [J]. Proc Natl Acad Sci USA，2012，109（31）：E2127-E2133.
[26] Lee JK，Lee J，Kim S，et al. Clonal History and Genetic Predictors of Transformation Into Small-Cell Carcinomas From Lung Adenocarcinomas [J]. J Clin Oncol，2017，35（26）：3065-3074.
[27] Taniguchi Y，Horiuchi H，Morikawa T. Small-Cell Carcinoma Transformation of Pulmonary Adenocarcinoma after Osimertinib Treatment：A Case Report [J]. Case Rep Oncol，2018，11（2）：323-329.
[28] Ham JS，Kim S，Kim HK，et al. Two Cases of Small Cell Lung Cancer Transformation from EGFR Mutant Adenocarcinoma During AZD9291 Treatment [J]. J Thorac Oncol，2016，11（1）：e1-e4.
[29] Poh ME，Liam CK，Rajadurai P. Epithelial-to-mesenchymal transition （EMT） causing acquired resistance to afatinib in a patient with epidermal growth factor receptor mutant lung adenocarcinoma [J]. J Thorac Dis，2018，10 （7）：E560-E563.
[30] Sakuma Y，Nishikiori H，Hirai S，et al. Prolyl isomerase Pin1 promotes survival in EGFR mutant lung adenocarcinoma cells with an epithelial-mesenchymal transition phenotype [J]. Lab Invest，2016，96（4）：391-398.